BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 24, 2004
View Archived Issues
Novel NMDA antagonists may protect neurons from ischemia-induced cell death
Read More
Phase I/II trial of human papillomavirus vaccine
Read More
Genentech reviews Q2 developments
Read More
Endothelin receptor antagonist attenuates diabetes-induced endothelial lesions
Read More
Menarini reports a new class of NK2 antagonists with potential as analgesic agents
Read More
New 5-HT6 antagonist with improved pharmacokinetic properties designed at GSK
Read More
A cyanoguanidine-based prodrug identified as a clinical candidate by Leo scientists
Read More
Endo acquires North American rights to Rapinyl
Read More
New modafinil formulation shows promise for children with ADHD
Read More
New antidiabetic agents in early development at Bayer
Read More
Novel SGLT2 inhibitors prepared and tested at Kissei
Read More
Bayer scientists design new MKK4 and/or MKK7 inhibitors
Read More
New antiobesity agents disclosed by Bayer in a recent patent
Read More
Boehringer Ingelheim claims novel factor Xa inhibitors
Read More
New inhibitors of ICAM-1/LFA-1-mediated cell adhesion and their use
Read More
New cannabinoid CB1 antagonist for use in obesity, cognitive disorders, etc.
Read More
ProIX obtains development and marketing rights for novel PI-3K inhibitors
Read More
Antiretroviral effects of statins indicate potential in HIV infection
Read More
Viragen updates Multiferon progress
Read More
Liprostin successfully completes phase II study in peripheral vascular disease
Read More
Alimta approved for second-line treatment of advanced lung cancer
Read More
Canadian approval for phase I study of Proxinium
Read More
Sanofi-Aventis is world's third largest pharma company
Read More
European MAA submission for clofarabine for pediatric leukemias
Read More
Orphan drug status for HuMax-CD4
Read More
Kyorin and Merck conclude license agreement
Read More
Zeria targets launches after 2006
Read More
Novel back-up candidate with vasopressin antagonist activity identified at Yamanouchi
Read More
Results of efficacy and pharmacokinetic studies of an anxiolytic prodrug
Read More